Dechra Pharmaceuticals (BATS-CHIXE:DPHL) - Cours de l'action, nouvelles et analyse

DPHL Aperçu des actions

Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. Plus de détails

DPHL analyse fondamentale
Score flocon de neige
Évaluation	1/6
Croissance future	4/6
Performances passées	0/6
Santé financière	1/6
Dividendes	0/6

Récompenses

Les bénéfices devraient augmenter 62.48% par an

Analyse des risques

Les paiements d’intérêts ne sont pas bien couverts par les bénéfices

Dechra Pharmaceuticals PLC Concurrents

Hikma Pharmaceuticals

LSE:HIK

UK£4.4b

HUTCHMED (China)

AIM:HCM

UK£2.4b

Indivior

LSE:INDV

UK£1.1b

GSK

LSE:GSK

UK£54.6b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Dechra Pharmaceuticals
Historique des cours de bourse
Prix actuel de l'action	UK£38.70
Plus haut sur 52 semaines	UK£38.84
Plus bas sur 52 semaines	UK£24.74
Bêta	0.78
1Variation sur 1 mois	0.55%
Variation sur 3 mois	2.27%
Variation sur 1 an	35.79%
3Variation sur 3 ans	5.91%
Variation sur 5 ans	63.71%
Évolution depuis l'introduction en bourse	744.98%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	DPHL	GB Pharmaceuticals	GB Marché
7D	0.2%	4.2%	1.7%
1Y	35.8%	3.0%	8.4%

Rendement vs Industrie: DPHL a dépassé le secteur UK Pharmaceuticals qui a rapporté 3 % au cours de l'année écoulée.

Rendement vs marché: DPHL a dépassé le marché UK qui a rapporté 8.4 % au cours de l'année écoulée.

Volatilité des prix

Is DPHL's price volatile compared to industry and market?
DPHL volatility
DPHL Average Weekly Movement	0.5%
Pharmaceuticals Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Cours de l'action stable: DPHL n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de DPHL a diminué de 6% à 1% au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1997	2,457	Ian Page	www.dechra.com

Dechra Pharmaceuticals PLC Résumé des fondamentaux

Comment les bénéfices et les revenus de Dechra Pharmaceuticals se comparent-ils à sa capitalisation boursière ?
DPHL statistiques fondamentales
Capitalisation boursière	UK£4.40b
Bénéfices(TTM)	-UK£27.90m
Recettes(TTM)	UK£761.50m

5.8x

Ratio P/S

-157.8x

Ratio P/E

Le site DPHL est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
DPHL compte de résultat (TTM)
Recettes	UK£761.50m
Coût des recettes	UK£331.90m
Marge brute	UK£429.60m
Autres dépenses	UK£457.50m
Les revenus	-UK£27.90m

Derniers bénéfices déclarés

Jun 30, 2023

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	-0.24
Marge brute	56.42%
Marge bénéficiaire nette	-3.66%
Ratio dettes/capitaux propres	64.6%

Quelles ont été les performances à long terme de DPHL?

Voir les performances historiques et les comparaisons

DPHL Aperçu des actions

Récompenses

Analyse des risques

Dechra Pharmaceuticals PLC Concurrents

LSE:HIK

UK£4.4b

AIM:HCM

UK£2.4b

LSE:INDV

UK£1.1b

LSE:GSK

UK£54.6b

Historique des prix et performances

Nouvelles et mises à jour récentes

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Less than half of directors are independent

Non-Executive Chairman recently bought UK£99k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Board Member recently sold UK£875k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold UK£963k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: UK£37.50

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: UK£35.98

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

Dechra Pharmaceuticals PLC Résumé des fondamentaux

5.8x

-157.8x

Bénéfices et recettes